Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.

Journal of the National Cancer Institute - 1 Jul 2014

Sclafani Francesco, Gonzalez David, Cunningham David, Hulkki Wilson Sanna, Peckitt Clare, Tabernero Josep, Glimelius Bengt, Cervantes Andrés, Dewdney Alice, Wotherspoon Andrew, Brown Gina, Tait Diana, Oates Jacqueline, Chau Ian

Abstract excerpt

In this updated analysis of the EXPERT-C trial we show that, in magnetic resonance imaging-defined, high-risk, locally advanced rectal cancer, adding cetuximab to a treatment strategy with neoadjuvant CAPOX followed by chemoradiotherapy, surgery, and adjuvant CAPOX is not associated with a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) in both KRAS/BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cetuximab
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase II as Topic

Share to Neoadjuvant Therapy

Share to Radiotherapy, Adjuvant

Share to Randomized Controlled Trials as Topic

Share to Rectal Neoplasms

Share to Sample Size

Source

Identifiers

PMID: 24957073
DOI: 10.1093/jnci/dju121

Genes

KRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.PMID 24957073Read ↗

RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial.Semantic proximity Read ↗

Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.Semantic proximity Read ↗

Can TP53, TMB and TME Expand the Immunotherapy Benefit in Metastatic Colorectal Cancer?Semantic proximity Read ↗

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.Semantic proximity Read ↗

TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.Semantic proximity Read ↗

KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.Semantic proximity Read ↗

Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: German Health Technology Assessment-Driven Analyses From the BEACON CRC Study.Semantic proximity Read ↗

Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.Semantic proximity Read ↗

Prediction of p53 mutation status in rectal cancer patients based on magnetic resonance imaging-based nomogram: a study of machine learning.Semantic proximity Read ↗

Diagnostic Accuracy of MRI Radiomics for Predicting KRAS Mutation in Rectal Cancer: A Systematic Review and Meta-analysisSemantic proximity Read ↗

Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.